Incretin-based therapies and cardiovascular risk.
作者： Edoardo Mannucci , Ilaria Dicembrini
DOI: 10.1185/03007995.2012.678940
关键词:
摘要: AbstractBackground:Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors are currently used as glucose-lowering agents in type 2 diabetes, due to their effects on insulin glucagon secretion. These agents, which effective improving glucose control, could also have a beneficial effect the incidence of cardiovascular events. The analysis major events reported during trials with metabolic endpoints shows significant reduction risk both classes drugs. Longer-term specifically designed assess GLP-1 DPP4 ongoing.Scope:In order elucidate potential mechanisms protection incretin-based therapies, Medline search (any date up December 15th, 2011) was performed using terms ‘cardiovascular’ (‘DPP-4’ or ‘GLP-1’ any single name drugs); papers were considered relevant for...
unifi.it
informahealthcare.com参考文章(69)
George G. Sokos, Hakki Bolukoglu, Judy German, Teresa Hentosz, George J. Magovern, Thomas D. Maher, David A. Dean, Stephen H. Bailey, Gary Marrone, Daniel H. Benckart, Dariush Elahi, Richard P. Shannon, Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. American Journal of Cardiology. ,vol. 100, pp. 824- 829 ,(2007) , 10.1016/J.AMJCARD.2007.05.022
M. Monami, I. Iacomelli, N. Marchionni, E. Mannucci, Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutrition Metabolism and Cardiovascular Diseases. ,vol. 20, pp. 224- 235 ,(2010) , 10.1016/J.NUMECD.2009.03.015
Matteo Monami, Francesco Cremasco, Caterina Lamanna, Claudia Colombi, Carla Maria Desideri, Iacopo Iacomelli, Niccolò Marchionni, Edoardo Mannucci, Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials Experimental Diabetes Research. ,vol. 2011, pp. 215764- 215764 ,(2011) , 10.1155/2011/215764
A. Schweizer, S. Dejager, J. E. Foley, A. Couturier, M. Ligueros-Saylan, W. Kothny, Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes, Obesity and Metabolism. ,vol. 12, pp. 485- 494 ,(2010) , 10.1111/J.1463-1326.2010.01215.X
J. Koska, E. A. Schwartz, M. P. Mullin, D. C. Schwenke, P. D. Reaven, Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. ,vol. 33, pp. 1028- 1030 ,(2010) , 10.2337/DC09-1961
Matteo Monami, Ilaria Dicembrini, Daniele Martelli, Edoardo Mannucci, Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion. ,vol. 27, pp. 57- 64 ,(2011) , 10.1185/03007995.2011.602964
J. J. Meier, A. Gethmann, O. Götze, B. Gallwitz, J. J. Holst, W. E. Schmidt, M. A. Nauck, Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans Diabetologia. ,vol. 49, pp. 452- 458 ,(2006) , 10.1007/S00125-005-0126-Y
Mathijs C. Bunck, Anja Cornér, Bjorn Eliasson, Robert J. Heine, Rimma M. Shaginian, Yan Wu, Ping Yan, Ulf Smith, Hannele Yki-Järvinen, Michaela Diamant, Marja-Riitta Taskinen, One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress Atherosclerosis. ,vol. 212, pp. 223- 229 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2010.04.024
M. Lenski, A. Kazakov, N. Marx, M. Böhm, U. Laufs, Effects of DPP-4 inhibition on cardiac metabolism and function in mice. Journal of Molecular and Cellular Cardiology. ,vol. 51, pp. 906- 918 ,(2011) , 10.1016/J.YJMCC.2011.08.001
K. Esposito, D. Cozzolino, G. Bellastella, M. I. Maiorino, P. Chiodini, A. Ceriello, D. Giugliano, Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. ,vol. 13, pp. 594- 603 ,(2011) , 10.1111/J.1463-1326.2011.01380.X